Apollo Drug Discovery Team

Home  /  Apollo People  /  Dr Ian Tomlinson
Ian Tomlinson


Apollo Therapeutics Chairman

Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454 million.  He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK.

Following he departure from GSK earlier this year, he is now  Chairman of the Board at the Stevenage Bioscience Catalyst, UK’s first open innovation biomedical campus.  He is also Chairman of the Investment Committee for Apollo Therapeutics, a £40 million fund dedicated to turning academic biotechnologies into novel medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.

 Dr Tomlinson graduated from Trinity College, Cambridge, UK.  He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.

Apollo aims to integrate academic research
and the biopharma industry